El interés en corto de Corbus Pharmaceuticals da a los inversores una idea del grado en que los inversores apuestan por la caída de las acciones de Corbus Pharmaceuticals. Los datos de interés en corto se actualizan cada dos semanas.

Corbus Pharmaceuticals (NASDAQ:CRBP) Bolsa, Informe de interés en corto

Corbus Pharmaceuticals

Corbus Pharmaceuticals Holdings Inc is a precision oncology company with a diversified portfolio and is committed to helping people defeat serious illness by bringing scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.

Corbus Pharmaceuticals Holdings, Inc. - Common Stock

Corbus Pharmaceuticals Holdings Inc

BIO-key Intl (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BKYI#NASDAQ">BKYI</a>) reported quarterly losses of $(0.39) per share which beat the analyst consensus estimate of $(0.58) by 32.76 percent.

Earnings

Earnings Beats

News

BKYI

BIO-key Intl Q3 2024 Adj EPS $(0.39) Beats $(0.58) Estimate

WIIM

TFFP

TFF Pharmaceutical shares are trading lower after the company announced it will wind down its operations.

Enveric Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENVB#NASDAQ">ENVB</a>) reported quarterly losses of $(0.24) per share which beat the analyst consensus estimate of $(0.52) by 53.85 percent.

ENVB

Enveric Biosciences Q3 2024 GAAP EPS $(0.24) Beats $(0.52) Estimate

AKYA

Akoya Biosciences shares are trading lower after the company reported worse-than-expected Q3 financial results.

Trading Ideas

DOCN

OKTA

Soros Fund Management 13F Shows Increased Put Position In SPDR S&P 500 ETF By 608% To 2,123,000 Shares; Increased Stake In Ishares Financial Select Sector SPDR ETF By 22,720% To 2,800,000 Shares; Increased Stake In JD.com By 114% To 2,730,000 Shares; Increased Stake In Okta Convertible Notes By 75% To $79.1M In Principal; Increased Stake In DigitalOcean Convertible Notes By 302% To $116.5M In Principal

Buybacks

Primerica Board Authorizes $450M Share Repurchase Program To Occur Through December 31, 2025

XPON

Expion360 shares are trading lower after the company reported a year-over-year decline in Q3 revenue results.

Asset Sales

BLFS

BioLife Solutions Sells Subsidiary, Arctic Solutions, For $6.1M

BENF

Beneficient Q2 2025 Revenue $8.6M Vs $(42.8M) YoY

Chardan Capital analyst Keay Nakae maintains Silence Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLN#NASDAQ">SLN</a>) with a Buy and maintains $55 price target.

Price Target

Analyst Ratings

Chardan Capital Maintains Buy on Silence Therapeutics, Maintains $55 Price Target

DBGI

DBGIW

Digital Brands Group shares are trading lower after the company reported worse-than-expected Q3 EPS results and a year-over-year decline in Q3 revenue.

As the U.S. prepares for what could be a defining legislative session for digital assets, expectations are mounting around potential <a href="https://www.benzinga.com/topic/crypto-regulations">shifts in crypto regulation</a>. 
Robert Leshner, CEO and co-founder of Superstate sees this as a turning point, with Congress possibly advancing long-awaited laws to provide clarity in the industry. 
Speaking ahead of the <a href="https://benzinga.swoogo.com/digital-assets/6342807">Benzinga Future of Digital Assets event</a>, Leshner shared his outlook on what might come next.
See Also: <a href="https://www.benzinga.com/economics/macro-economic-events/24/11/41984825/trump-rally-fades-as-investors-await-powells-remarks-bitcoin-drops-below-90000-whats-driving-markets-thursday">Trump Rally Fades As Investors Await Powell&#8217;s Remarks, Bitcoin Drops Below $90,000: What&#8217;s Driving Markets Thursday?</a>
<h3 class="wp-block-heading">A New Framework for Digital Assets</h3>
With the prospect of a Congress more favorable to digital assets, Leshner anticipates that lawmakers will focus on three core areas: a framework for stablecoins, structured definitions for digital assets, and repealing the SEC's SAB-121 guidance on crypto custody. 
He pointed out the impact of these potential regulations, explaining that they could finally end a "decade of legal grays" and replace it with "black and white rules" that would allow the industry to expand within a clear legal structure.
<figure class="wp-block-image size-full"><a href="https://benzinga.swoogo.com/digital-assets/6342807"><img loading="lazy" decoding="async" width="300" height="250" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/13235418/905735A6-57D3-4874-9AA1-75D037842DB3-1-13.gif" alt="" class="wp-image-646877" /></a></figure>
<h3 class="wp-block-heading">Addressing Stablecoins and Custody Rules</h3>
One priority on the legislative horizon is a stablecoin bill that would establish guidelines for stablecoins in the U.S. The proposed law aims to clarify the issuance and management of stablecoins, which have become widely used in digital transactions. 
Leshner also emphasized the potential impact of repealing the SEC's SAB-121 guidance, which has restricted crypto custody by placing complex accounting requirements on crypto-related firms. Removing these restrictions, he believes, would open new possibilities for digital asset custody services in the U.S.
<h3 class="wp-block-heading">Defining Crypto Assets</h3>
Leshner highlighted the importance of clear definitions for digital assets, noting that confusion around terminology has long been a barrier for the industry. Proposed measures such as FIT21 aim to categorize digital assets, creating a structured approach that could aid mainstream adoption. Leshner views these definitions as essential for aligning crypto with existing financial regulations, creating a foundation for the industry to grow.
As Leshner prepares to speak at the <a href="https://benzinga.swoogo.com/digital-assets/6342807">Benzinga Future of Digital Assets</a> event, his perspective offers insight into how upcoming legislation could reshape the future of digital finance in the U.S.
<hr class="wp-block-separator has-alpha-channel-opacity" />
As the digital asset market continues to mature, the convergence of regulatory shifts, M&amp;A activities, and adoption trends will define the future of this dynamic field.&nbsp;<a href="https://www.benzinga.com/digital-assets" target="_blank" rel="noreferrer noopener">Benzinga's Future of Digital Assets</a>&nbsp;event in New York City this November will provide industry leaders and investors with a platform to explore these developments further, offering insights into the evolving regulatory environment and the latest market dynamics.
Image via Unsplash

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Events

Exclusives

Interview

Could New Legislation Finally Bring Clarity To US Crypto Rules? Industry Expert Weighs In

LBRDA

MCHP

Soros Fund Management 13F Shows Added Put Position In SPDR S&P 500 ETF With 2,123,000 Shares; Added Stake In Smurfit Westrock With 6,896,971 Shares; Added Put Position In Ishares Russell 2000 ETF With 800,000 Shares; Added Stake In Microchip Technology Convertible Notes With $130.3M In Principal;  Added Stake In Liberty Broadband Corp With 1,119,893 Shares; Added Stake In AstraZeneca With 2,652,771 Shares

SPAI

Safe Pro Group Q3 Revenue $330.756K Up From $163.547K YoY

IPower shares are trading lower after the company reported worse-than-expected Q1 financial results.

MGRM

Monogram Technologies Q3 EPS $(0.16) Down From $(0.03) YoY

Chardan Capital analyst Geulah Livshits maintains 4D Molecular Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FDMT#NASDAQ">FDMT</a>) with a Buy and maintains $39 price target.

FDMT

Chardan Capital Maintains Buy on 4D Molecular Therapeutics, Maintains $39 Price Target

Snap Inc&#8216;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNAP#NYSE">SNAP</a>) Snapchat is introducing a new real-time location sharing feature designed for family members, allowing users to share their live<a href="https://www.benzinga.com/topic/consumer-tech"> locations with others. </a>
The update will roll out in the coming weeks, alongside new privacy and location tools. This feature is aimed at improving user safety, especially for parents tracking their teens' whereabouts, the company <a href="https://parents.snapchat.com/parental-controls">announced. </a>
See Also: <a href="https://www.benzinga.com/news/24/10/41618021/snap-touts-new-ad-formats-and-simple-snapchat-10m-users-trial-growth-driving-feature">Snap Touts New Ad Formats And &#8216;Simple Snapchat&#8217; — 10M Users Trial Growth-Driving Feature</a>
Once available, the Family Center will include an option for parents to request their child&#8217;s location, and vice versa. The platform will also allow users to view and adjust location-sharing settings, alongside other privacy controls. 
Additionally, Snapchat will enable automatic travel notifications, alerting family members when someone arrives at or leaves specific locations, such as home or school.
<h3 class="wp-block-heading">Snapchat&#8217;s Privacy And Safety Concerns</h3>
While the new features have practical uses, their timing has sparked debate.<a href="https://parents.snapchat.com/parental-controls"> According </a>to The Verge, the app is currently involved in a lawsuit filed by New Mexico&#8217;s attorney general, Raúl Torrez, who claims Snapchat failed to act on warnings about the platform being used to target minors for "sextortion" and other forms of exploitation. 
Torrez has also criticized the app's design, which automatically deletes messages, photos, and videos after a set time, arguing that it complicates efforts to keep users safe.
The company's decision to roll out location sharing in the midst of these legal challenges may lead to additional scrutiny, especially as it relates to the platform's ability to protect its users' privacy. 
In response to these concerns, Snapchat is making location-sharing an opt-in feature, available only to friends and family. Users will also receive prompts to review their privacy settings when adding new connections.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/24/02/37306324/instagram-is-working-on-a-snapchat-like-friends-map-feature-heres-how-it-works">Instagram Is Working On A Snapchat-like &#8216;Friends Map&#8217; Feature: Here&#8217;s How It Works</a></li>
</ul>
Photo: Diego Thomazini/Shutterstock.com

Social Media

Tech

SNAP

Snapchat Puts Family On The Map With New Real-Time Locator

Florida GOP Senator <a href="https://www.benzinga.com/topic/marco-rubio">Marco Rubio</a> is President-elect <a href="https://www.benzinga.com/topic/donald-trump">Donald Trump</a>'s <a href="https://www.benzinga.com/24/11/41959835/trump-nominates-marco-rubio-as-secretary-of-state-calls-florida-senator-a-powerful-voice-for-freedom">pick for the role</a> of Secretary of State.
Trump praised Rubio (53) as a "highly respected leader" and a "powerful voice for freedom." But, will he be that open-minded when it comes to cannabis policy reform?
Judging by his earlier stance, what's left for cannabis shareholders and advocates, is hope.
<h3 class="wp-block-heading">Rubio Is Just Not That Into Cannabis</h3>
In a 2022 <a href="https://www.youtube.com/watch?v=63UZT6rEAdQ">interview</a> with a Pensacola TV station, Rubio revealed his reasons for taking a stance against federal cannabis legalization. The concept of cannabis as a "gateway" drug, or one leading users to more dangerous drugs, was one of his main concerns.
&#8220;When you decriminalize something, the message that you&#8217;re basically sending people is it must not be that bad,&#8221; Rubio said, as <a href="https://www.benzinga.com/markets/cannabis/22/04/26666538/marco-rubio-reveals-why-he-opposes-cannabis-legalization">highlighted</a> by Benzinga's <a href="https://www.benzinga.com/author/nina-zdinjak">Nina Zdinjak</a>. &#8220;Now, suddenly, you&#8217;re an 18- or 17-year-old, [and you] say,&nbsp;&#8216;well, I know marijuana, you tell me not to smoke it, but you know what? It can&#8217;t be that bad, because the federal government made it legal.'&#8221;
At the time, Rubio also argued that cannabis bought from illegal sources has been&nbsp;<a href="https://www.benzinga.com/markets/cannabis/19/09/14451540/report-synthetic-marijuana-fentanyl-found-in-cbd-labeled-products">laced with the strong opioid fentanyl</a>, a drug involved in about 30,000 overdose deaths last year.&nbsp;
Read Also: <a href="https://www.benzinga.com/news/global/24/11/41893397/trump-reportedly-considers-marco-rubio-for-secretary-of-state-role-who-shares-similar-stance-for-china-but-says-stock-market-is-not-the-economy">Trump Reportedly Considers Marco Rubio For Secretary Of State Role Who Shares Similar Stance For China, But Says Stock Market &#8216;Is Not The Economy&#8217;</a>
<ul>
<li>Get Benzinga's exclusive analysis and the top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter <a href="https://newsletteremail.benzinga.com/subscribe" target="_blank" rel="noreferrer noopener">here</a>. If you're serious about the business, you can't afford to miss out.</li>
</ul>
Asked by the Daily Mail nearly a decade ago whether he ever used cannabis, Rubio answered ambiguously, <a href="https://reason.com/2015/02/04/why-wont-marco-rubio-admit-he-smoked-pot/">reported</a> Reason. 
"I&#8217;ll tell you why I never answer that question,&#8221; he said back in 2014. &#8220;If I tell you that I haven&#8217;t, you won&#8217;t believe me. And if I tell you that I did, then kids will look up to me and say, &#8216;well, I can smoke marijuana because look how he made it.'&#8221;
That&#8217;s because there's "no responsible way to recreationally use" marijuana, according to Rubio, <a href="https://www.huffpost.com/entry/marco-rubio-marijuana_n_5352382">reported</a> HuffPost.
This stance doesn't come as a surprise considering that in 2014 he expressed his support for continued criminal penalties for recreational cannabis use. "I don&#8217;t think legalizing marijuana or even decriminalizing it is the right decision for our country,&#8221; Rubio said as <a href="https://www.tampabay.com/opinion/2024/09/19/better-justice-system-florida-should-legalize-recreational-marijuana-heres-why/">reported</a> by Tampa Bay.
Moreover, during his unsuccessful 2016 presidential campaign, he openly supported cracking down on states that have legalized marijuana and enforcing the law, that prohibits marijuana, <a href="https://www.browardpalmbeach.com/news/marco-rubio-says-hed-crack-down-on-marijuana-if-elected-president-7174851">reported</a> Broward Palm Beach New Times. "I believe the federal government needs to enforce federal law,&#8221; he said at the time.
<h3 class="wp-block-heading">But…</h3>
Interestingly, Rubio also said medical use of cannabis is something he could consider if it is the non-psychoactive type.
In 2016, he reiterated his stance on the recreational use of cannabis, but slightly amended his view on medical marijuana, <a href="https://www.washingtontimes.com/news/2016/feb/11/rubio-no-responsible-way-habitual-marijuana-use/">reported</a> the Washington Times. He said "If there's a medicinal use — if you can go to the FDA and prove that it helps with medicine, that's fine. Then turn it into medicine."
Keeping in mind that Rubio once referred to Trump as "the most vulgar person," one cannot help but wonder whether Rubio will take a U-turn on cannabis. Or is the saying "The fox changes its fur but not its vice," a more probable scenario?
Read Next:
<ul>
<li><a href="https://www.benzinga.com/24/11/41950826/kristi-noems-appointment-as-homeland-security-secretary-raises-questions-about-federal-cannabis-policy">Trump&#8217;s Appointment Of Kristi Noem To Homeland Security Chief Raises Questions About Fed Cannabis Policy</a></li>
</ul>

Cannabis

Government

Politics

Trump Says His Secretary Of State Pick Marco Rubio Is 'Powerful Voice For Freedom' – But What About Cannabis?

PLTR

Palantir Technologies shares are trading higher after the company announced it will transfer its stock exchange listing over to the Nasdaq.

Corbus Pharmaceuticals (CRBP) presents new pre-clinical data at Obesity Week 2024 further characterizing CRB-913, its highly peripherally restricte...

Corbus Pharmaceuticals presents new CRB-913 pre-clinical data at Obesity Week

Andres Y. Maldonado, an analyst from H.C. Wainwright, maintained the Buy rating on Corbus Pharmaceuticals (CRBP – Research Report). The associated ...

Corbus Pharmaceuticals' CRB-913: A Promising and Safer Alternative in Obesity Treatment with a Buy Rating

Mizuho Securities analyst Graig Suvannavejh has maintained their bullish stance on CRBP stock, giving a Buy rating yesterday. Graig Suvannavejh has...

Buy Rating for Corbus Pharmaceuticals on Promising CRB-913 Obesity Treatment and Favorable Risk/Reward Scenario

As of September 30, 2024, the Company had $159.4 million in cash, cash equivalents and investments on hand, which is expected to fund operations th...

Corbus Pharmaceuticals expects cash to fund operations through 3Q27

"We continue to make steady and significant progress across our pipeline," said Yuval Cohen, Ph.D., Chief Executive Officer of Corbus. "We expect t...

Corbus Pharmaceuticals reports Q3 EPS ($1.15), consensus (95c)

An update from Corbus Pharmaceuticals ( ($CRBP) ) is now available. Corbus Pharmaceuticals, an oncology and obesity-focused company, reported a net...

Corbus Pharmaceuticals Reports Q3 2024 Financial Results

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include:&nbsp...

Biotech Alert: Searches spiking for these stocks today

H.C. Wainwright analyst Andres Maldonado lowered the firm's price target on Corbus Pharmaceuticals (CRBP) to $75 from $80 and keeps a Buy rating on...

Corbus Pharmaceuticals price target lowered to $75 from $80 at H.C. Wainwright

In a report released on November 7, Brian Abrahams from RBC Capital maintained a Buy rating on Corbus Pharmaceuticals (CRBP – Research Report), wit...

Corbus Pharmaceuticals (CRBP) Receives a Buy from RBC Capital

Corbus Pharmaceuticals' Sell-Off: Speculative Entry Price In Oncology And Obesity Therapies

ALKS

APLS

CRBP

DERM

ELAB

NKTR

NONOF

RPRX

SNYNF

TKPHF

VKTX

VRCA

VRNA

The Future of Medicine: Key Biotech Stocks to Watch

Press Releases

Corbus Pharmaceuticals to Present at the 2024 Cantor Global Health Conference

Transforming Oncology: Stocks to Watch in the Oncology Sector

Transforming Cancer Therapy Stocks to Watch In The Oncology Sector

Corbus Pharmaceuticals to Participate in the BMO Capital Markets' Oncology Summit

Corbus Announces Enrollment Completion of Dose Escalation Stage of Phase 1 Clinical Trial of Its Next Generation Nectin-4 Targeting ADC (CRB-701)

Corbus Pharmaceuticals to Present at the Guggenheim Securities Healthcare Innovation Conference

Corbus Pharmaceuticals Presents New CRB-913 Pre-Clinical Data At Obesity Week 2024

Corbus Pharmaceuticals Reports 3rd Quarter 2024 Financial Results and Provides a Corporate Update

Health Care

Corbus Pharmaceuticals to Present at the Jefferies London Healthcare Conference

ACON

ATNM

OSTX

PBYI

Acrivon Therapeutics, Inc. - Common Stock

Acrivon Therapeutics

Adaptimmune Therapeutics plc - American Depositary Shares

Adaptimmune Therapeutics

Amarin Corporation plc - American Depositary Shares, each representing one Ordinary Share

Comments

Corbus Pharmaceuticals

Interés en corto

Corbus Pharmaceuticals (NASDAQ:CRBP) Bolsa, Informe de interés en corto

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL